Synageva Biopharma Corp (GEVA) 108.51 $GEVA Next Week In

New Post Public Reply Private Reply Replies (0) Message Board

Apr 26, 2015 at 2:57 PM

Synageva Biopharma Corp (GEVA) 108.51 $GEVA

Next Week In Biotech: Gilead, Celgene Report; PDUFAs For Theravance, The Medicines Co.
SA Editor Mike Taylor - Seeking Alpha - Fri Apr 24, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
VRX: 210.42 (+1.03), BMRN: 120.28 (-2.67), UTHR: 186.69 (-1.87), CLDX: 30.10 (+0.19), ACOR: 33.12 (-0.38), AFFX: 12.44 (-0.16), HSP: 87.61 (-0.05), OXGN: 1.48 (unch), MACK: 13.42 (-0.25), HBIO: 6.22 (+0.08), ECYT: 6.17 (-0.13), GEVA: 108.51 (+0.92), CYTR: 5.13 (-0.13), THRX: 17.92 (+0.46), FF: 11.18 (+0.03), MDXG: 9.81 (-0.39), EXEL: 3.08 (-0.02), VRTX: 133.20 (-2.62), NEO: 4.75 (-0.11), PFE: 35.27 (-0.09), INCY: 107.34 (-0.51), MYL: 76.06 (+2.37), AMGN: 167.91 (-1.26), ANIK: 38.35 (-0.32), ALKS: 62.26 (-1.19), ONTY: 1.74 (-0.05), CELG: 118.71 (+2.62), NBIX: 43.37 (-0.31), SGEN: 37.14 (-0.36), OGXI: 2.19 (+0.04), EBIO: 11.19 (+0.69), ABAX: 63.62 (+0.31), GILD: 103.69 (-1.52), GERN: 4.30 (-0.03), HAE: 43.35 (+0.74), MRK: 57.60 (+0.09), TEVA: 64.41 (+1.16), PCRX: 85.07 (+0.80)

Synageva BioPharma Submits Kanuma(TM) (Sebelipase Alfa) Application For LAL Deficiency In Mexico
PR Newswire - Mon Mar 30, 6:05AM CDT
Synageva BioPharma Corp. (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, announced today the submission to the Comisión Federal para la Protección contra Riesgos Sanitarios (Cofepris) in Mexico for Kanuma as a treatment for patients with lysosomal acid lipase deficiency (LAL Deficiency), a rare genetic disease with significant morbidity and early mortality. The submission to Cofepris for Kanuma included previously reported data from the global, randomized, double-blind, placebo controlled Phase 3 trial in children and adults with LAL Deficiency, and the Phase 2/3 trial of Kanuma in infants with LAL Deficiency.
GEVA: 108.51 (+0.92)

Today's Weak On High Volume Stock: Synageva BioPharma (GEVA)
at The Street - Thu Mar 26, 9:03AM CDT
Trade-Ideas LLC identified Synageva BioPharma (GEVA) as a weak on high relative volume candidate
GEVA: 108.51 (+0.92)

The Best Stocks To Buy This Week
Todd Campbell - at Seeking Alpha - Tue Mar 17, 6:56AM CDT

ELLI: 57.75 (+0.69), JCOM: 71.05 (+0.03), CAH: 91.38 (-0.12), CIEN: 22.17 (+0.48), AET: 108.82 (-0.08), ANAC: 64.49 (-2.10), CSL: 99.55 (+0.47), HSIC: 142.54 (+0.70), CAVM: 65.63 (-4.51), HAS: 71.61 (-0.10), MCHP: 47.33 (-1.24), COLM: 62.84 (+0.73), DEPO: 27.65 (+0.36), HRL: 54.85 (-0.03), COO: 181.75 (-1.24), DYAX: 27.44 (-0.85), LVLT: 54.67 (+0.05), CBRL: 142.08 (+0.67), AZO: 702.00 (-0.33), EQIX: 246.07 (-0.86), KNX: 31.45 (-0.14), HAE: 43.35 (+0.74), EL: 82.26 (-0.19), FSL: 38.86 (-1.12), CCK: 55.29 (+0.45), BLL: 74.56 (+2.09), CDW: 38.87 (-0.15), ADBE: 76.54 (+0.02), AFFX: 12.44 (-0.16), AGN: 240.22 (+2.88), DPS: 78.86 (-0.09), INFA: 48.16 (+0.16), APH: 56.17 (-0.53), GEVA: 108.51 (+0.92), LII: 108.00 (+0.75), GMED: 24.79 (+0.15), BJRI: 49.52 (-3.92), DPZ: 113.96 (+4.73), HBI: 32.22 (-2.36), FL: 60.86 (+0.14), DLX: 67.37 (-0.17), ABT: 48.32 (-0.14), KR: 71.70 (+0.77), ABCO: 52.24 (+0.30), DIOD: 27.28 (-0.72), LEG: 44.31 (+0.21), DIS: 109.53 (+0.53), GLW: 22.52 (-0.27), MAR: 81.84 (+0.49), LEA: 115.08 (-0.97), DISH: 69.91 (+0.30), IMAX: 37.62 (+0.22), CNC: 73.67 (+1.13), CTAS: 82.13 (-0.18), CMCSA: 59.64 (+0.41), FLO: 22.31 (-0.20), BIG: 47.57 (-0.16), CRM: 67.83 (-0.64)

Synageva BioPharma's (GEVA) CEO Sanj Patel on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Feb 26, 9:02PM CST

GEVA: 108.51 (+0.92)

Synageva BioPharma misses by $0.02, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Feb 26, 3:10PM CST

GEVA: 108.51 (+0.92)

Synageva BioPharma To Host 2014 Fourth Quarter And Full Year Financial Results Conference Call On February 26
PR Newswire - Thu Feb 19, 8:00AM CST
Synageva BioPharma Corp. (Synageva) (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare diseases, will report 2014 fourth quarter and full year financial results after the NASDAQ Market closes on Thursday, February 26, 2015. Synageva management will conduct a conference call and audio webcast to discuss these results as well as provide a general business update at 4:30 p.m. EST on the same day.
GEVA: 108.51 (+0.92)

A Look at the Latest Occurrences in the Healthcare Sector: Special Research on Sangamo BioSciences,Seattle Genetics, StemCells, Synageva and VBI Vaccines
PR Newswire - Thu Feb 19, 6:50AM CST
Editor Note: For more information about this release, please scroll to bottom.
GEVA: 108.51 (+0.92), SGEN: 37.14 (-0.36), STEM: 0.61 (-0.21), SGMO: 14.70 (-0.84), VBIV: 2.61 (+0.08)

Synageva European Patent Issued For Treatment Of LAL Deficiency
PR Newswire - Wed Feb 18, 6:30AM CST
Synageva BioPharma Corp. (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, announced today that the European Patent Office issued European Patent No. EP2613798 B1 relating to the treatment of lysosomal acid lipase deficiency (LAL Deficiency). This patent provides protection until 2031, not including any patent term extension.
GEVA: 108.51 (+0.92)

Synageva BioPharma Announces Presentations At 11th Annual World Symposium
PR Newswire - Wed Feb 11, 6:30AM CST
Synageva BioPharma Corp. (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, announced today that data related to the company's programs will be the subject of three oral presentations and one poster presentation at the WORLDSymposium(TM) conference, February 9-13 in Orlando, Florida.
GEVA: 108.51 (+0.92)

An $8 Billion Hedge Fund Bought This Extremely Risky Stock: Should You?
George Budwell, The Motley Fool - Motley Fool - Sun Feb 01, 12:02PM CST
The market activity of billionaire investors tends to attract a lot of attention because these billionaires are often perceived as having some kind of special insight into the direction of the broader market or individual stocks. In the world of...
ACAD: 38.36 (-0.54), PCYC: 256.59 (-0.51), BMRN: 120.28 (-2.67), GEVA: 108.51 (+0.92)

Synageva Starts Dosing in Phase I/II Study for Sanfilippo B - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 28, 5:25PM CST
Synageva BioPharma Corp. (GEVA) has commenced patient dosing in a phase I/II study on SBC-103 for mucopolysaccharidosis IIIB (also known as Sanfilippo B syndrome).
BMRN: 120.28 (-2.67), GEVA: 108.51 (+0.92), RGDO: 1.42 (+0.13), CELG: 118.71 (+2.62)

Synageva BioPharma Announces Dosing Of Patients Commenced With SBC-103 In Phase 1/2 Study For Mucopolysaccharidosis IIIB And FDA Fast Track Designation Granted
PR Newswire - Mon Jan 26, 6:30AM CST
Synageva BioPharma Corp. (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, announced today dosing with SBC-103 in patients with mucopolysaccharidosis IIIB (MPS IIIB, also known as Sanfilippo B syndrome) has begun as part of a Phase 1/2 study. In addition, the U.S. Food and Drug Administration (FDA) recently granted SBC-103 Fast Track designation. Fast Track is a process designed to facilitate development and expedite review of drugs to treat serious and life-threatening conditions and fill an unmet medical need to get important new drugs to patients expeditiously.
GEVA: 108.51 (+0.92)

Why You Shouldn't Bet Against Synageva BioPharma (GEVA) Stock - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 12, 7:58AM CST
Synageva BioPharma (GEVA) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective
GEVA: 108.51 (+0.92)

3 Biotech Stocks Focused on Curing Ultra-Rare Diseases
Sean Williams, The Motley Fool - Motley Fool - Sun Jan 11, 1:41PM CST
Source: Food and Drug Administration. Biotech companies have a difficult battle they need to face on a daily basis. On one hand, they want to help as many people as possible and improve patients' quality of life around the globe with their...
GEVA: 108.51 (+0.92), BMRN: 120.28 (-2.67), ALXN: 180.08 (-4.50)

InsiderInsights.com Daily Round Up 1/9/15: OAS, OPK, RM, VVUS
InsiderInsights - at Seeking Alpha - Sun Jan 11, 12:09AM CST

PATK: 60.86 (+0.04), SVU: 10.86 (-0.05), VVUS: 2.46 (-0.04), BBY: 35.39 (-0.74), CRDS: 2.50 (-0.06), RM: 14.66 (-0.10), BRT: 6.80 (-0.04), WIW: 11.55 (+0.04), UNFI: 70.76 (+0.06), GEVA: 108.51 (+0.92), OPK: 14.83 (+0.17), CUDA: 46.12 (+0.24), NSAM: 21.58 (+0.04), WYY: 1.52 (-0.03), OAS: 16.26 (-0.20), RFP: 15.89 (-0.09), CRM: 67.83 (-0.64), NRF: 18.97 (+0.02)

Synageva BioPharma Announces Pricing of Public Offering of Common Stock
PR Newswire - Tue Jan 06, 6:07PM CST
Synageva BioPharma Corp. (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, today announced the pricing of its previously announced underwritten public offering of common stock consisting of 3.0 million shares at $94.19 per share. In connection with this offering, Synageva granted to the underwriters a 30-day option to purchase 450,000 additional shares of common stock. If the underwriters exercise this option, Synageva will have offered 3.45 million shares of its common stock.
GEVA: 108.51 (+0.92)

Can The Uptrend Continue for Synageva Biopharma (GEVA)?

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Blue Moon Metals Gears Up for Springer Mine Revamp

Getting Set for a Big Move Blue Moon Metals Inc. isn't sitting around with its thumbs in its pockets. The company has made some strides with their Springer Tungsten Mine project in Imlay, Nevada. Let's break down what these folks are up to. Refurbished Up for the Fast Track The rock mover here is the refurbishment of the Springer processing plant. You don't just snap your...

ASICS and University of Michigan Launch Innovation Lab

Running Innovation Gets a Boost in Ann Arbor On a crisp fall day up in Ann Arbor, ASICS and the University of Michigan have decided it's high time to shake up the world of running product R&D. These two powerhouses just launched the ASICSx Michigan Sport Innovation Center (AMSI), an academic-industry research lab. It's like they're mixing college smarts with business...

Ambient AI Shows Promise for Boosting Cancer Care Efficiency

Study Points to Ambient AI's Promise in Oncology Some days, the world of cancer care is a real beast to tackle. But today, we've got a glimpse into how technology, and specifically ambient AI, might just help slay some of the burdens that these healthcare warriors face daily. The Florida Cancer Specialists & Research Institute (FCS) joined hands to dive into how this tech...

Netcapital's 28.62% Plunge: A Fraudulent Drama Unfolds

Netcapital: The Plunge Heard 'Round the Market There it is, clear as day—Netcapital’s (NASDAQ: NCPL) stock plummeting 28.62% like a lead balloon. Shareholders had to watch in horror as pieces of their investments seemed to evaporate, all thanks to a swirl of alleged fraud. You can't just shrug off accusations that a company you've betted on has been cooking its books,...

Boscia's Future Ties Tradition and Modern Science

Reviving a Skincare Legacy With the wind of innovation at its back, The Center Brands and Dr. Mamina Turegano are stepping in to breathe new life into Boscia. Now, I'm not just talking about a simple facelift. We're talking about an all-out integration of traditional Japanese skincare principles with the sharp edge of modern dermatologic science. It's a brave move...

University of Phoenix Grads Gain High Praise from Managers

Forget the stereotypes that tag University of Phoenix as just another factory for diplomas. The latest survey results paint a picture of graduates who seem to be real go-getters in the workplace. We’ve got managers from all over singing the praises of these alums, with a whopping 96% ready to vouch for them stepping into bigger roles. Not just talk, folks, this is their...

Elbit Systems Lands $200M APAC ISTAR Contracts

By Ryan Hughes Updated Oct 26, 2026 Category News Views 100

Elbit Systems Secures Major Asia-Pacific Deal You know, it's not every day that a defense contractor like Elbit Systems (NASDAQ:ESLT) bags a $200 million deal in the Asia-Pacific region. A big move in a high-stakes game where technology, strategy, and geography collide. This isn't some random supply deal; this involves the cutting edge of defense tech—ISTAR and training...

Medline's Decade-Long WRAP Partnership: More Than Labels

A Decade of Trust and Responsibility Here we go, folks—Medline is toasting 10 years with WRAP, and this ain't just fluffy PR spin. When two big players like these lock arms over responsible manufacturing, it's a signal worth paying attention to, and not just for the ethics alone. Production practices that prioritize transparency and worker rights have ramifications...

Gentex Faces Investigation as Shares Tumble 7%

Investigating Gentex's Financial Setback Gentex Corporation, ticker NASDAQ:GNTX, is caught in a bit of a blizzard right now. Their shares took a nosedive, down 7%, after some messy numbers came out in their third-quarter report—tariffs and the kind of pricing pressure that makes grown investors wince. If you threw your chips in on Gentex and got burned, the lawyers are...

MacDonald Steps Up as President at California Bank

New Leadership at California Bank & Trust It's a big shakeup in the banking lanes today as Michael MacDonald grabs the helm at California Bank & Trust (CB&T). He's stepping into the President's shoes, bringing along a toolkit of experience and know-how that's tough to find elsewhere. Under his watch, CB&T aims to blend the nimble maneuvering of local banks with the clout...